
Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.
The






